Michael Bogart1, Mrudula B Glassberg2, Tyler Reinsch3, Richard H Stanford3. 1. GSK, 5 Moore Drive, Research Triangle Park, NC, USA. Electronic address: michael.r.bogart@gsk.com. 2. Ethicon, US Route 22, Somerville, NJ, USA. 3. GSK, 5 Moore Drive, Research Triangle Park, NC, USA; Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
BACKGROUND: It is unknown whether there is a benefit to initiating triple therapy (TT; inhaled corticosteroids combined with long-acting β2-agonists and long-acting muscarinic antagonists) promptly (within 30 days) following a chronic obstructive pulmonary disease (COPD)-related hospitalization or emergency-department (ED) visit compared with delaying treatment (31-180 days). METHODS: This retrospective, observational study (GSK: HO-15-15256) used healthcare claims from a commercial and Medicare claims database (January 1, 2008-December 31, 2015). PATIENTS: ≥40 years of age, diagnosed with COPD and no history of TT 12 months pre-index. Patients experiencing a COPD-related hospitalization or ED visit (index) who initiated TT ≤ 6 months following index were included (January 1, 2009-December 31, 2014). Patients initiating TT ≤ 30 or 31-180 days following index were included in the Prompt or Delayed cohorts, respectively. All-cause and COPD-related costs (total, medical and prescription), and exacerbations (severe and moderate) per patient per year were determined for 12 months post index. Outcomes were adjusted by cohort, weighted for a balanced distribution of baseline covariates between cohorts using inverse probability weights. RESULTS: Overall, 10,902 patients were identified (Prompt: n = 5701; Delayed: n = 5201). Total, medical and prescription all-cause costs were significantly higher in the Delayed versus Prompt cohorts (percent increase: 18.7%, 22.8% and 8.8%, respectively; all p < 0.0001). COPD-related total, medical and prescription costs were 49.3%, 66.3% and 10.3% higher in the Delayed versus Prompt cohorts, respectively (all p < 0.0001). Total and severe COPD-related exacerbation rates were 28.2% and 64.7% higher in the Delayed versus Prompt cohorts (p < 0.0001). CONCLUSION: Prompt use of TT following a COPD-inpatient or ED visit may reduce future costs and subsequent exacerbations compared with delaying the initiation of TT.
BACKGROUND: It is unknown whether there is a benefit to initiating triple therapy (TT; inhaled corticosteroids combined with long-acting β2-agonists and long-acting muscarinic antagonists) promptly (within 30 days) following a chronic obstructive pulmonary disease (COPD)-related hospitalization or emergency-department (ED) visit compared with delaying treatment (31-180 days). METHODS: This retrospective, observational study (GSK: HO-15-15256) used healthcare claims from a commercial and Medicare claims database (January 1, 2008-December 31, 2015). PATIENTS: ≥40 years of age, diagnosed with COPD and no history of TT 12 months pre-index. Patients experiencing a COPD-related hospitalization or ED visit (index) who initiated TT ≤ 6 months following index were included (January 1, 2009-December 31, 2014). Patients initiating TT ≤ 30 or 31-180 days following index were included in the Prompt or Delayed cohorts, respectively. All-cause and COPD-related costs (total, medical and prescription), and exacerbations (severe and moderate) per patient per year were determined for 12 months post index. Outcomes were adjusted by cohort, weighted for a balanced distribution of baseline covariates between cohorts using inverse probability weights. RESULTS: Overall, 10,902 patients were identified (Prompt: n = 5701; Delayed: n = 5201). Total, medical and prescription all-cause costs were significantly higher in the Delayed versus Prompt cohorts (percent increase: 18.7%, 22.8% and 8.8%, respectively; all p < 0.0001). COPD-related total, medical and prescription costs were 49.3%, 66.3% and 10.3% higher in the Delayed versus Prompt cohorts, respectively (all p < 0.0001). Total and severe COPD-related exacerbation rates were 28.2% and 64.7% higher in the Delayed versus Prompt cohorts (p < 0.0001). CONCLUSION: Prompt use of TT following a COPD-inpatient or ED visit may reduce future costs and subsequent exacerbations compared with delaying the initiation of TT.
Authors: Antoni Sicras Mainar; Alicia Huerta; Ruth Navarro Artieda; Eduard Monsó; Sarah H Landis; Afisi S Ismaila Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-09-12
Authors: Morgan Justice Fuoco; Richard A Mularski; Benjamin Wu; Chad Moretz; Mary Ann McBurnie; Richard H Stanford; Phillip Crawford; Daniel Gratie; Bianca Salas Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-10-07
Authors: Joseph Tkacz; Kristin A Evans; Daniel R Touchette; Edward Portillo; Charlie Strange; Anthony Staresinic; Norbert Feigler; Sushma Patel; Michael Pollack Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-02-10
Authors: David Mannino; Michael Bogart; Guillaume Germain; Shirley P Huang; Afisi S Ismaila; François Laliberté; Young Jung; Sean D MacKnight; Marjorie A Stiegler; Mei Sheng Duh Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-03-05
Authors: Hanna Sandelowsky; Christer Janson; Fredrik Wiklund; Gunilla Telg; Sofie de Fine Licht; Björn Ställberg Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-08-09